REVEAL GENOMICS, S.L.: ESMO 2022: REVEAL GENOMICS? PRESENTS

Presented during the ESMO Congress 2022, HER2DX? predicts the response of trastuzumab, pertuzumab and letrozole in patients with HER2+ HR+ breast cancer.This is the first study to show the ability

Related Keywords

France , Paris , France General , Hebron , Israel General , Israel , Spain , Barcelona , Comunidad Autonoma De Cataluna , Pierfranco Conte , Kostenloser Wertpapierhandel , Adriana Herrera , Valentina Guarneri , Aleix Prat , Investigacions Biom , European Society Of Medical Oncology Congress , University Of Barcelona , Twitter , Hebron Institute Of Oncology , Research Use Only , University Of Padova , European Society , Medical Oncology Congress , Translational Genomics , Targeted Therapeutics , Hebron Institute , Reveal , Genomics , Osmo , 022 , Presents , Validation , Data , Her2dx , Erelisa , Trial ,